Get started
Author

Niara Oliveira

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
2024 · Thomas Powles, James W.F. Catto, et al. · New England Journal of Medicine · 491
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
2024 · Tivya Kulasegaran, Niara Oliveira · Current Treatment Options in Oncology · 92
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer
2016 · Brittney S Harrington, Yaowu He, et al. · British Journal of Cancer · 75
PDF
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study
2025 · K. Fizazi, N.W. Clarke, et al. · Annals of Oncology · 71
PDF
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance
2015 · Y He, A C Wu, et al. · Oncogene · 62
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
2026 · Matthew D. Galsky, Begoña P. Valderrama, et al. · New England Journal of Medicine · 42
EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface
2014 · M N Adams, B S Harrington, et al. · Oncogene · 41
Cancer in Pregnancy
2019 · Naomi Eastwood‐Wilshere, Jessica Turner, et al. · Asia-Pacific Journal of Clinical Oncology · 38
PDF
Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report
2014 · Thomas P Moloney, Wen Xu, et al. · BMC Ophthalmology · 24
PDF
SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma
2025 · Thomas B. Powles, Enrique Grande, et al. · Future Oncology · 13
PDF
Ecstasy intoxication: the toxicological basis for treatment
2003 · Maristela Ferigolo, Adriana G. da S. Machado, et al. · Revista do Hospital das Clínicas · 9
PDF
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia
2023 · Howard Gurney, Timothy D. Clay, et al. · Asia-Pacific Journal of Clinical Oncology · 8
PDF
2383O A phase III study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281
2025 · K. Fizazi, N.W. Clarke, et al. · Annals of Oncology · 6
RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC.
2026 · Thomas Powles, Vadim S. Koshkin, et al. · Journal of Clinical Oncology · 4
PDF
Genomic variation in symptom expression in castrate-resistant prostate cancer
2025 · Janet Hardy, Ristan Greer, et al. · BMJ Supportive & Palliative Care · 1
Factors Affecting Quality Control (QC) Failure Rates in Somatic Breast Cancer ( BRCA ) Gene Testing in Castrate Resistant Prostate Cancer: Experiences From an Australian Cancer Care Centre
2025 · Cian O'Leary, Edward Yoong, et al. · Asia-Pacific Journal of Clinical Oncology · 1
Metastatic uterine leiomyosarcoma at 26 weeks gestation
2019 · Naomi Eastwood-Wilshere, Jessica Turner, et al. · BMJ Case Reports · 1
Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer
2026 · Dickon Hayne, Shomik Sengupta, et al. · Asia-Pacific Journal of Clinical Oncology
Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281
2026 · K. Fizazi, N.W. Clarke, et al. · Annals of Oncology
PDF
Patient and Physician Preferences for Treatment in Advanced Renal Cell Carcinoma in Asia-Pacific (PEAR)- A Discrete Choice Experiment
2026 · Alison Zhang, Niara Oliveira, et al. · Research Square
PDF
Patient and physician preferences for treatment in advanced renal cell carcinoma (PEAR): An international, multi-centre discrete choice experiment (DCE).
2026 · Alison Yan Zhang, Bryan Li, et al. · Journal of Clinical Oncology
503P Treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), real-world adoption of combination therapies in Australia and Asia
2025 · A. Anton, J.Y. Joung, et al. · Annals of Oncology
Os04.5.a a Phase 2 Study of Pemigatinib for Pre-treated Glioblastoma or Other Gliomas With Activating Fgfr1-3 Alterations: Final Results From Fight-209
2025 · E Franceschi, M van den Bent, et al. · Neuro-Oncology
PDF
271O Interim analysis (IA) of SPADE: A prospective, real-world study of avelumab first-line maintenance (1LM) treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Asia-Pacific (APAC) region
2024 · S.H. Park, J. Jo, et al. · Annals of Oncology
PDF
Adjuvant immunotherapy for high‐risk renal cell carcinoma—now or never?
2024 · Tivya Kulasegaran, Niara Oliveira, et al. · British Journal of Urology
Works count: 32
Citation count: 1,050
H-index: 11
I10-index: 11
Year
Topic
Type